Capsugel Produces DPI Phase 2 Trial Supplies
PTSM: Pharmaceutical Technology Sourcing and Management
Capsugel extends inhaled biotherapeutics delivery capability to Phase 2 clinical trials.
Capsugel announced on May 4 that the company has manufactured Phase 2 clinical trial supplies for a dry powder inhalation (DPI) formulation that delivers biotherapeutics to the lung. The supplies were manufactured by Bend Research, part of Capsugel’s Dosage Form Solutions business unit.
The inhaled dry-powder biotherapeutic, which was developed using particle engineering and spray-drying processing methods, is the first inhalation delivery therapy to be manufactured to Phase 2 scale at the company’s clinical trial manufacturing facility in Bend, OR.
The spray-dry technology and particle engineering provides a stable dry powder with improved aerosol performance and high collection efficiencies, the company reports. The DPI powders will be dosed in a Phase 2 clinical trial in 2015.
Capsugel reports that it will add commercial spray-drying capacity this year, enabling the company to manufacture DPI formulations at commercial scale.
Source: Capsugel
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
